Reducing squalene epoxidase by the aging-dependent intra-tissue cholesterol accumulation is associated with increased colorectal cancer patient severity in high-risk populations.

*Short title:** Reduction of SQLE increases CRC patient severity.

[1,4]**Soo Young Jun**, [2]Hyang Ran Yoon, [1]Ji-Yong Yoon, [1]Jeong-Ju Lee, [3]Jin-Man Kim and [1,4]*Nam-Soon Kim

[1]Rare Disease Research Center, [2]Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience & Biotechnology, Daejeon 34141, Korea

[3]College of Medicine, Chungnam National University, Daejeon, 305-764, Korea

[4]Functional Genomics, University of Science & Technology, Daejeon 34113, Korea

*Abbreviations:** SQLE, squalene epoxidase; CRC, colorectal cancer; GSK3β, glycogen synthase 3β; ROC, receiver operating characteristic; timeROC, time-dependent ROC; PFS, progression-free survival; SEER, Surveillance, Epidemiology, and End Results; NHNES, National Health and Nutrition Examination Survey; AUC, area under the curve;

*Correspondence to:**

Nam-Soon Kim[1,4*], Rare Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, South Korea. E-mail: nskim37@kribb.re.kr; Tel.: 82-42-

879-8112; Fax: 82-42-879-8119.

__Authors' contribution:__

study concept and design-SYJ and NSK

acquisition of data-SYJ and HRY

analysis and interpretation of data-SYJ, HRY and NSK

drafting of the manuscript-SYJ and NSK

critical revision of the manuscript for important intellectual content-SYJ and NSK

statistical analysis-SYJ and HRY

obtained funding-NSK

technical or material support- JYY and JJL

study supervision-NSK

__Conflicts of interest:__ The authors disclose no conflicts.

ABSTRACT

Reducing squalene epoxidase by the aging-dependent intra-tissue cholesterol

accumulation is associated with increased colorectal cancer patient severity in high-

risk populations.

Objective: Recently, we demonstrated cholesterol accelerating colorectal cancer (CRC)

progression via squalene epoxidase (SQLE) reduction, activating the β-catenin oncogenic

pathway while downregulating the p53 pathway, mediated by the inhibition of GSK3β activity

(GSK3β^{pS9}). However, the interrelationship between cholesterol increase and CRC

progression with aging has never been determined.

Design: We utilized case data from public databases and human specimens to assess the

relationship between cholesterol accumulation and CRC progression with aging. Digital image

analysis-machine learning with multiplex fluorescence-immunohistochemistry evaluated the

effects of SQLE, p53^{WT}, p53^{MT}, and GSK3β^{pS9} (hereafter candidates) on the survival of CRC

patients. Also, the prognostic and diagnostic abilities were assessed by a time-dependent

receiver operating characteristic (timeROC) and a ROC curve with and without the

discriminant score for the candidates as a single or whole, respectively.

Results: We found an accumulation of cholesterol and cholesteryl ester in tissues with aging,

which led to the acceleration of CRC progression through substantial decreases of SQLE,

p53^{WT}, p53^{MT} expressions and inhibition of GSK3β activity in advanced CRCs. Retrospective

studies demonstrated that SQLE significantly impacted the shortened progression-free

survival of the population with progressive pathological severity and high CRC risk beyond the

age of 50. Clinical assays further showed the excellent prognostic and diagnostic abilities of

SQLE and GSK3β^{pS9} but also the substantial diagnostic potential of the combined candidate

for the aged high-risk CRC population.

Conclusion: We provide new insights into the relationship between cholesterol increase and

CRC progression with aging and identify valuable biomarkers for aged populations with high-

risk CRC.

***Keywords:** Colorectal cancer; Lipoprotein-Cholesterol, Gastrointestinal cancer; Squalene

epoxidase; Glycogen Synthase Kinase 3β; p53; Digital image analysis-machine learning with

multiplex fluorescence-immunohistochemistry

INTRODUCTION

Colorectal cancer (CRC) is the second leading cause of cancer-related death globally[1], even with advances in screening technology and an increasing detection ratio at earlier stages. Moreover, most CRC patients' deaths are associated with metastatic CRCs[2,3]. Therefore, identifying biomarkers related to patients with high-risk CRC is crucial for implementing appropriate surveillance and treatment protocols.

CRC incidence and mortality increase with age, not only showing significant growth beyond age 50[4]: the most prevalent group at risk of CRC with mostly diagnosed between ages 65 and 74 years, but also a recent noticeable increase in patients under 50 (early-onset CRC). Due to the current rise in high-cholesterol diets, several societies, such as the Korean Society of Gastrointestinal Cancer Research[5] and the US Preventive Services Task Force[6], have renewed their CRC screening recommendation to include adults ages 50 to 75 but also those ages 45 to 49 years. Abualkhair's recent report[7] further supports that using a subsequent one-year age model, the significant ratio of CRC incidence between ages 49 and 50 represents unidentified early-onset CRC detected later via screening after age 50. Moreover, despite ongoing debate, multiple epidemiological studies point to a cholesterol/low-density lipoprotein-related lifestyle as the cause for increased CRC fatality[8,9] and early-onset CRC incidence[10]. However, the age-dependent interrelationship between cholesterol increase and CRC progression has never been elucidated.

Nevertheless, of its essential to maintaining cell membrane integrity and providing the precursor for several vital substances such as steroid hormones and vitamin D, overproduction of cholesterol harms the cells but also the organs. Relatedly, studies have reported that high serum cholesterol levels contribute to malignant colonic transformation by causing hypoxia in large intestine tissues[11,12]. Thus, the delicate adjustment of intra-cellular cholesterol content is

required. Squalene epoxidase (SQLE) has been reported as a bona fide oncogene in several

cancers, including breast[13] and liver[14], and also is considered a rate-limiting enzyme in

cholesterol biosynthesis[15,16]. In addition, Gill et al., and others reported that cholesterol

exquisitely regulates the SQLE gene and protein by suppressing SQLE expression and

inducing proteasomal degradation of the SQLE protein via MARCHF6-ubiquitination at the N-

terminal 100 amino acid[15,16]. Notably, we demonstrated this disconnection under certain

pathologic conditions on the expression of the SQLE gene and protein[17]; SQLE degradation

caused by accumulated cholesterol over a certain threshold accelerates CRC progression and

metastasis via activating the β-catenin oncogenic pathway by inhibiting the p53 anti-tumor

suppressor path and GSK3β activity. In this study, we assessed the age-dependent

relationship between cholesterol increase and CRC progression using CRC specimens

grouped according to patient age and cancer grade with a machine learning analysis of

digitized whole slide images through retrospective evaluation. We found the underlying

relationship between aging-dependent intra-tissue cholesterol augmentation and CRC

progression via SQLE reduction for the old population with high CRC risk beyond age 50.

MATERIALS AND METHODS

Sources of patients' samples

We constructed a discovery cohort, split into training and testing sets, using human

specimens supplied by TissueArray.com (previously, US Biomax, Derwood, MD, USA; Table

1). Additionally, we validated the results of this discovery cohort using retrospectively collected

human samples from Chungnam National University Hospital (Daejeon, South Korea). To

determine the content of intra-tissue total cholesterol and cholesteryl ester, as well as the intra-

tissue levels of the candidates, we obtained frozen human CRC samples with patient

information from BIOBANK (Chungnam National University Hospital, Daejeon, South Korea).

The studies with TissueArry.com and Chungnam Nation University Hospital were exempted

by the Public Institution Bioethics Committee designated by the Ministry of Health and Welfare

and the Research Ethics Committee of the Korean Research Institute of Bioscience and

Biotechnology (P01-202104-31-006 and 2021-0838-001, respectively).

The content of intra-tissue total cholesterol and cholesteryl ester

The content of intra-tissue total cholesterol and cholesteryl ester were determined

according to the manufacturer's instructions. Briefly, CRC tissues were homogenized in a

mixture (chloroform: isopropanol: NP-40; 7:11:0.1, respectively). Then, every liquid phase

after centrifugation at 15,000g was vacuum air-dried at 50°C for 30 minutes. To measure the

total cholesterol and free cholesterol, the reaction mixture with and without cholesterol

esterase was mixed with the extraction dissolved in the assay buffer. The total and free

cholesterol levels were determined at OD570nm after incubating the reaction mixture at 37°C

for 60 minutes. The cholesteryl ester concentration was calculated by subtracting the value of

the free cholesterol from the total cholesterol value.

Western blotting

A Western blot was performed, as we previously reported[17]. Briefly, tissue lysates

were prepared in ice-cold Pierce IP Lysis/Wash Buffer (Thermo Fisher Scientific, 87788),

separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred onto

nitrocellulose membranes, and blocked with the indicated antibodies also used for multiplex

fluorescence-based immunohistochemistry. The specificity of the antibodies was evaluated in

our previous study[17].

A multiplex fluorescence-based immunohistochemistry

As previously described[17], the levels of SQLE, $p53^{WT}$, $p53^{MT}$, and $GSK3\beta^{pS9}$ in human

tissues were determined. Briefly, deparaffinized and antigen-retrieved slides were reacted with

antibodies against SQLE, $p53^{WT}$, GSK3β (Santa Cruz Biotechnology, Dallas, TX, USA; SC-

99144, SC-126, SC-377213, respectively), $p53^{MT}$ (Abcam, Boston, MA, USA; ab32049), and

$GSK3\beta^{pS9}$ (Cell Signaling Technology, Danvers, MA, USA; 9323s) overnight. Afterward, each

slide was reacted with Alexa Fluor-633 goat anti-rabbit, -546 goat anti-mouse, or -488 goat

anti-mouse antibody (Thermo Fisher Scientific, Waltham, MA, USA; A21071, A11030, or

A11001, respectively). Confocal observation (LSM800, Carl Zeiss, Oberkochen, Germany)

was then performed. To evaluate antibody specificity, thyroid cancer tissues were stained with

the same antibodies and then observed under a confocal microscope (Supplementary Figure

4), confirming the negative responsiveness of the SQLE antibody in thyroid cancer given in

the report "The human protein atlas (https://www.proteinatlas.org/ENSG00000188404-

SELL/pathology).

Statistical analysis

An unpaired *t*-test was used to determine a statistical significance; all *p* values were

noted in each figure. All statistical analysis was performed using *R* and *SPSS*. For the

quantitative analysis of SQLE, $p53^{WT}$, $p53^{MT}$, and $GSK3\beta^{pS9}$ (hereafter candidates) in CRC

tissues, we performed global normalization[18] as follows; once divided by GSK3β median

intensity, each value was log-transformed, then individual log values were subtracted by the

median log value of each group. The levels of the candidates were represented as the median

with the standard error of the mean. A uni-, multivariate Cox proportional hazard and Kaplan-

Meier method based on the log-rank test were used for survival analyses. To determine the

prognostic and diagnostic abilities of the candidates, we applied a time-dependent receiver

operating characteristic (timeROC) and ROC curves with or without a discriminant score.

TimeROC utilized a weighted Cox regression for survival data to determine the area under the

timeROC curve. The timeROC and ROC curves without a discriminant score were obtained

using *R*, while ROC curves with a discriminant score were based on *SPSS*.

RESULTS

Epidemiological study

We used case data from the Surveillance, Epidemiology, and End Results (SEER)

program to verify the recent incidence and mortality trend of CRC. Based on the SEER

guidelines[19], we categorized the following cancer sub-types as colon cancer: appendix,

ascending, cecum, descending, transverse, sigmoid, hepatic flexure, splenic flexure, and

rectosigmoid segment colon, excluding anal cancer[20] due to most cancerous changes similar

to cervical cancer infected with human papillomavirus (HPV).

Our analysis verified the significant statistical ratio between ages 49 and 50 in which

early-onset CRC (CRCs diagnosed before 50) was detected beyond age 50 via screening

uptake (Supplementary Figure 1A), consistent with Abualkhair's report[7]. In addition, we

evaluated increased early-onset CRC incidence[10] and mortality (Supplementary Figure 1B, C)

and reduced CRC death rate decline[8,9] (Supplementary Figure 2), which are considered

dietary cholesterol intake-related characteristics. Moreover, given the age-dependent CRC

incidence and mortality, we determine if cholesterol levels increase with age using data from

the National Health and Nutrition Examination Survey (NHNES). Notably, in both sexes, the

percentage of those reporting high cholesterol increased with age, especially in 2015-2018

(Supplementary Figure 3A, B). Therefore, our epidemiological analysis strongly supports an

aging-dependent association between CRC incidence/mortality and cholesterol increase.

Evaluation of cholesterol accumulation and CRC progression with aging

In light of our recent report[17] on cholesterol accumulation and its acceleration of CRC progression through SQLE reduction, which activates the β-catenin oncogenic pathway and inhibits the p53/21 tumor suppressor pathway, we examined the expression levels of SQLE, p53^{WT}, p53^{MT} and the phosphorylation of GSK3β^{pS9} on age-dependent CRC progression using human tissue microarray sections to reduce between-subject variability. Besides, we employed two types of p53 antibodies, p53^{WT} and p53^{MT}, which are reported to detect mainly wild-type and mutant p53, respectively.

We found a significant decrease in the expression of SQLE, p53^{WT}, and p53^{MT} and increase in GSK3β^{pS9} phosphorylation between ages 50-70 compared with those between 20-30 (Figure 1A, B). These findings were confirmed by a different cohort (Figure 1C, D). In addition, consistent with our previous report, we corroborated a significantly decreased SQLE, p53^{WT}, and p53^{MT} expressions and increased GSK3β^{pS9} phosphorylation during CRC progression (Figure 1E). Of note, we verified the significant downregulation of p53^{WT} but also p53^{MT} in the aged and aggressive CRCs, partially explained by our previous demonstration[17] that overexpression of p53 wild type, but also p53R273H, having partial transactivation activity[17], with the treatment of HLI373, an Mdm2 inhibitor suppressed cell survival in SQLE-reduced condition. Moreover, the involvement of SQLE, p53^{WT}, p53^{MT} and GSK3β^{pS9} during CRC progression was further supported by the staining of thyroid cancer tissues with antibodies against the candidates then observed under confocal microscopy (Supplementary Figure 4), showing no age-dependent difference, especially in SQLE expression and therefore corroborating our previous report that SQLE reduction due to cholesterol accumulated is a distinctive feature during the progression of gastrointestinal cancers.

We then assessed the age-dependent relationship between cholesterol augmentation

and CRC progression using CRC tissue lysates. The intra-tissue levels of total cholesterol and

cholesteryl ester significantly increased between ages 20-30 and 50-70 (Figure 2A, B). Notably,

cholesterol failed to show a significant increase between G2 and G3 (Figure 2A, B) as a higher

accumulation of cholesterol within G3 tissues degraded SQLE further (Figure 2C: red boxes,

D). Moreover, consistent with the observation in the digital analysis using tissue microarray

(Figure 1), the augmented reduction of SQLE expression further accelerated CRC progression,

as evidenced by a further decrease in $p53^{WT}$ and $p53^{MT}$ expressions and increase in $GSK3\beta^{pS9}$

phosphorylation in advanced CRCs (Figure 2C: red boxes, D).

Overall, the results demonstrate that aging-dependent accumulated cholesterol inside

tissue expedites CRC progression via additional reduction of SQLE, leading to increased

downregulation of $p53^{WT}$ and $p53^{MT}$ expression by upregulated inhibition of $GSK3\beta$ activity in

advanced CRCs.

Relevance of high-risk CRC candidates

Considering the cholesterol augmentation-CRC aggressiveness axis, we then

assessed the potential effects of SQLE, $p53^{WT}$, $p53^{MT}$, and $GSK3\beta^{pS9}$ (hereafter candidates)

on increasing CRC risk through a retrospective analysis of collected specimens from CRC

patients and controls. Table 1 shows the clinicopathological characteristics of the discovery

cohort; The cohort consisted of twice as many male patients, consistent with most reports on

male prevalence in CRC incidence and mortality, as well as adenocarcinoma (88.2%), the

most common subtype found in approximately 90% of CRC patients. Also, this cohort has

TNM staging, with a similar patient distribution across all stages, enabling estimation of CRC

aggressiveness and the cancer patients having shortened progression-free survival (PFS)

compared with the control. Therefore, this discovery cohort has sufficient characteristics to

evaluate the candidates' clinical implications in increasing CRC progression and patient

survival (Table 1).

Next, we randomly split the discovery cohort into training (70%) and testing sets (30%)

by apply a random forest-based modeling based on the machine-learning approach (Table 1;

Supplementary Table 1, 2). Then, the Cox proportional hazard regression analysis (hereafter

Cox analysis) was used to determine whether pathological-related variables and the

candidates as a single or whole impact CRC patients' PFS. Notably, we found the significant

effects of not only Sex (males), the pathological variables including stages, TNM, and grade,

but also SQLE on the survival of CRC patients beyond 50 (Supplementary Tables 1, 2; Figure

3). Interestingly, while $p53^{WT}$ and $GSK3\beta^{pS9}$ showed a significant hazard ratio (HR) associated

with the survival of the aged population in the testing and training sets, respectively: this HR

ratio was not confirmed in the other set, possibly caused by the bias of censored data to one

set. Furthermore, compared with patients under 50, the pathological-related variables,

including stage, TNM, and grade, showed a significantly increased HR ratio regarding the

survival of CRC patients beyond 50, indicating increased pathological severity in the aged

CRC patients (Figure 3; Supplementary Tables 1, 2). Moreover, the increased pathological

severity observed in older CRC patients was consistent was a shortened PFS for CRC patients

beyond 50 compared to those under 50, as demonstrated by the Cox and KM analyses (Figure

3, 4; Supplementary Tables 1, 2).

Overall, our study provides evidence for the crucial role of SQLE on the survival of the

aged populations with a high risk of CRC showing increased pathological severity, in contrast

to $p53^{MT}$ impacting the survival of those under 50 (Figure 3, 4; Supplementary Table 1, 2).

Clinical verification of candidates in populations at high CRC risk

We further evaluated whether the candidates could distinguish between patients who

would die or survive within a given time (t). For this purpose, we utilized a time-dependent

ROC (timeROC)[21] analysis that employed a weighted Cox regression for survival data to

determine the area under the timeROC curve: the times that maximize the area under the

curve (AUC) ratio was 123 and 137 months for patients before and after 50, respectively

(Figure 5). Importantly, SQLE, which showed a critical impact on the PFS of the aged

population with high CRC risk (Figure 3), also demonstrated remarkable prognostic ability in

discriminating between CRC patients over 50 who would die or survive within 137 months but

not in those under 50 (Figure 5). Interestingly, although the significant HR values of GSK3β^{pS9}

regarding the survival of the aged populations at the training test failed to be confirmed in the

testing set, we found that, unlike p53^{WT}, which showed its significant association with the aged

populations in the testing set, GSK3β^{pS9} had an important prognostic ability verified in both

sets (Figure 5).

Consistent with the prognostic abilities, SQLE and GSK3β^{pS9} showed satisfactory

diagnostic efficiencies with AUC values of 0.8 and 0.7 in distinguishing CRCs from controls,

respectively, in contrast to p53^{WT} and p53^{MT} (Supplementary Figure 5). Moreover, the

excellent diagnostic capacities of SQLE and GSK3β^{pS9} were corroborated by the ROC curve,

which utilized the discriminant score derived from each candidate in distinguishing CRC

patients from controls (Figure 6A, B). Notably, when all candidates were merged to calculate

the discriminant score for CRC patients above 50, a significant differential distribution was

observed compared to the control group. However, this was not observed in patients under

age 50 (Figure 6C-F: left). The observed differential distribution conformed with the excellent

AUC ratios of 0.87 and 0.85 in patients over 50 in the training and testing sets, respectively,

compared to AUC values of 0.48 and 0.65 in patients under 50 (Figure 6C-F: right).

Therefore, our analysis suggests SQLE and GSK3β[pS9] as potential biomarkers for

prognosis and diagnosis in the aged populations with high-risk CRC. Of note, we also show

the substantial diagnostic ability of the merged candidate, SQLE, p53[WT], p53[MT], and GSK3β[pS9]

for the aged high-risk CRC population (Figure 5, 6; Supplementary Figure 5).

Discussion

South Korea, exhibiting an increasing trend in intake of a westernized/cholesterol

diet[22] similar to most developed countries, shows the third-highest global CRC mortality ratio

for patients over 50 and the second-highest CRC incidence ratio for those under 50[1]. In this

study, we also verified a substantial increase in early-onset CRC incidence and mortality, as

well as an age-dependent cholesterol increase, by analyzing case data from the Surveillance,

Epidemiology, and End Results (SEER) program and the National Health and Nutrition

Examination Survey (NHNES), respectively. However, although its correlation has been

suggested[6-8], the mechanisms underlying cholesterol increase and CRC progression with

aging have yet to be fully elucidated.

Recently, we demonstrated[17] that cholesterol accumulated over a threshold point

accelerates SQLE degradation leading to the activation of the β-catenin oncogenic path,

mediated by the inhibition of GSK3β activity and the disruption of the p53 tumor suppressor

pathway and consequently aggravating CRC progression and metastasis. However, even

though our proof-of-concept results show the cause-and-effect relationship between

cholesterol increase and CRC progression, our conclusion needed to be revised because

most of our studies were performed in cell lines and animals. Therefore, we applied human

CRC and control specimens grouped according to patient age and cancer grade, as well as

multiplex fluorescence immunohistochemistry with digital image analysis based on machine

learning to evaluate the age-dependence between cholesterol increase and CRC progression.

Despite reports linking obesity and CRC[23], epidemiological findings between serum

lipids, especially in LDL, cholesterol, and CRC risk and progression have been conflicting[24].

In contrast, some studies, including Dessi[25] et al. and others[26,27,] have reported a higher total

cholesterol level in cancer tissues, including gastrointestinal cancer, than in normal tissues.

We also have demonstrated[17] that the accumulation of cholesterol within tumor cells worsens

CRC. This cholesterol buildup is partially caused by the increased expression of the low-

density lipoprotein receptor (LDLR) and the decreased expression of Adenosine triphosphate

(ATP)–binding cassette transporter 1 (ABCA1) in gastrointestinal cancers. As an extension of

our recent report, we found a significant augmentation of the intra-tissue total cholesterol and

cholesteryl ester with aging accelerating CRC progression; the more cholesterol accumulated

in aged CRC tissues, the more SQLE degraded, resulting in an increased lower expression of

$p53^{WT}$ and $p53^{MT}$ and a higher level of $GSK3\beta^{pS9}$ in advanced CRCs. Therefore, our study

provides the underlying mechanisms between the aging-dependent intra-tissue cholesterol

accumulation and CRC progression via SQLE reduction.

Despite technological advances, the five-year survival rate for distant colorectal

cancer is only 17%, compared to 90% for localized cancer[28]. Moreover, CRC mortality has

increased from fourth place in 2018 to third place globally in 2020, despite most cancers

showing a decline in mortality rates, according to Global Cancer Observatory (GLOBOCAN),

together, suggesting new biomarkers are required for populations with high CRC risk. In this

study, we demonstrated a critical association between SQLE, controlled by cholesterol, and

the shortened progression-free survival (PFS) of populations with high-risk CRC beyond age

50, having increased pathological severity, in contrast to $p53^{MT}$ in those under 50. Besides,

although it failed to be confirmed in both sets, which may be caused by the bias of censored

patient survival, we found that p53^{WT} and GSK3β^{pS9} had a statistical association with the aged

populations in testing and training sets, respectively. Furthermore, clinical assays showed the

excellent prognostic and diagnostic capabilities of SQLE but also GSK3β^{pS9} for the aged

populations with high-CRC risk beyond age 50. Interestingly, the discriminant assays using

the merged candidates showed substantial diagnostic ability in distinguishing from control to

CRC for the aged high CRC populations. Therefore, our study provides novel biomarkers

including SQLE, GSK3β^{pS9}, and the merged candidates for the aged high-risk CRC population

to implement appropriate surveillance and treatment protocols.

Previously, we demonstrated[17] that overexpression of ectopic p53 wild type and

p53R273H, which had a partial transactivation activity, along with the treatment of HLI373, an

Mdm2 inhibitor, suppressed the survival of SQLE-depleted CRC cells. However, p53-R273H-

mTAD, which mutated at four key residues (L22Q/W23SW53W/F54S), which had no

functional activity, failed to suppress SQLE-depleted cancer cells' survival. Thus, in this study,

we applied two types of antibodies to detect mainly wild-type (DO-1) and mutant p53, denoted

as p53^{WT} and p53^{MT}, respectively. We found a statistical reduction of p53^{WT} and p53^{MT} in

aggressive and aged CRCs, with p53^{WT} exhibiting approximately twice the relative decrease

of p53^{MT}. In addition, p53^{WT} had a partial association with the older population in the testing

set, while p53^{MT} had a critical association with the survival of the population under 50,

confirmed in both sets. However, unlike SQLE and GSK3β^{pS9}, which had an association with

the survival of the aged population and showed significant diagnostic and prognostic abilities,

p53 did not exhibit its efficacy, likely because p53 is a downstream target controlled by SQLE

and GSK3β.

Overall, this study corroborates our earlier demonstration that SQLE, via its N-terminal

100 amino acids, directly interacts with active GSK3β and p53, thereby modulating cancer cell

proliferation. Conversely, cholesterol helps cancer cells overcome this cellular barrier by

reducing SQLE, thereby downregulating the p53/p21 tumor suppressor pathway leading to

the activation of the β-catenin oncogenic pathway via GSK3β inhibition. Therefore, these

findings underscore the critical role of SQLE, GSK3β^{pS9}, and p53 in the survival of aging-

dependent accumulated cholesterol-accelerated CRC patients.

Previously, we demonstrated[17] that a 2% high cholesterol diet induced the pronounced

pathological progression and metastasis of CRC by SQLE reduction and robust production of

colon-cancer-originating migrating cancer stem cells (collectively indicated by the enrichment

of CDCP1 and CD110). Furthermore, in the 2% cholesterol CRC metastasis model, the

expression of SQLE was notably decreased in circulating tumor cells (CTCs) extracted using

anti-CDCP1 and CD110 antibodies. Thus, in the extension of the current study, we are

currently evaluating the diagnostic and prognostic potential of the candidates SQLE, p53^{WT},

p53^{MT}, GSK3β^{pS9}, CDCP1, and CD110 in CTCs.

Despite these promising results, our study has several limitations.

First, we obtained human tissue samples primarily from a commercial company rather

than through accredited hospitals. Thus, we tried to avoid possible issues by performing the

followings: We prepared a report using the checklist provided by the STrengthening the

Reporting of Observational Studies in Epidemiology (STROBE)[29]. In addition, to ensure

unbiased data analysis, the discovery cohort was split into a training and testing set using a

random forest modeling program which can eliminate the researcher's bias. Also, the results

obtained from the training set were verified by using the testing set and a separate cohort from

Chungnam National University Hospital.

Second, we did not investigate the serum levels of lipids or cholesterol in CRC patients

evaluated for the intra-tissue levels of candidates and cholesterol accumulation. However,

previous epidemiological studies[24] have shown inconsistent findings regarding the association

between serum lipids/cholesterol and CRC risk/progression, unlike other reports, including

we[17] and Dessi[25], which have consistently demonstrated the accumulation of cholesterol in

gastrointestinal CRC tissues and its association with CRC aggressiveness. Our current study

further supports the crucial role of intra-tissue accumulated cholesterol and cholesteryl ester

in promoting CRC progression.

Third, SQLE has been reported as a bona fide oncogene in several types of

cancers[13,14]. Recently, Li C et al., demonstrated[30] that overexpression of SQLE accelerates

the development of colorectal cancer by enhancing cancer cell proliferation and causing gut

dysbiosis. In line with this observation, we discovered[17] that SQLE is upregulated in human

CRC compared to normal tissues. Conversely, we and public databases, including Oncomine

databases-Simith and Kiaser, found SQLE decrease according to the course of CRC

progression, a unique characteristic in gastrointestinal cancers. Therefore, these results imply

that SQLE has a dual role in CRC formation and progression, respectively; SQLE contributes

to providing the cholesterol necessary for the formation of CRC; on the other hand, cholesterol

accumulated inside the tissue downregulated SQLE, thereby accelerating the β-catenin

oncogenic pathway through the inhibition of the p53/p21 tumor suppressor pathway and

GSK3β activity.

Finally, our study was limited by its small sample size. Thus, a larger cohort study

under the supervision of accredited hospitals will be necessary to validate and determine the

possible clinical usability of the candidate biomarkers. Finally, our study was limited by its

small sample size, and thus a larger cohort study under the supervision of accredited hospitals

will be necessary to validate and determine the possible clinical usability of the candidate

biomarkers.

In conclusion, our study demonstrates cholesterol accumulation within gastrointestinal

tissues during aging and how this process accelerates CRC progression. Furthermore, we

have provided novel biomarkers or panels that may be useful in identifying individuals in older

populations at high risk for colorectal cancer.

FIGURE LEGENDS

Figure 1. Involvement of SQLE, $p53^{WT}$, $p53^{MT}$, and $GSK3\beta^{pS9}$ in aging-dependent CRC

progression. Each CRC specimen grouped according to patient age (A-D) or CRC grade (E)

was stained simultaneously with antibodies against the indicated candidate and then observed

under confocal microscopy. The quantification of each variable shown in (A) and (C) was

presented in (B) and (D), respectively (Table 1). The tissues were supplied by TissueArray (A-

B, E) or Chungnam National University Hospital (C-D). $p53^{WT}$, mainly detecting wild-type p53

(DO-1), $p53^{MT}$; mainly mutant p53 (Y5), and $GSK3\beta^{pS9}$: the inactive form of $GSK3\beta$ determined

by the anti-$GSK3\beta^{pS9}$ antibody. Scale bar, 100 μm. *An unpaired t-test determined P values.

Figure 2. Relevance of cholesterol augmentation in age-related CRC progression. The total

cholesterol (A) and cholesteryl ester (B) in CRC tissue lysates were measured according to

the manufacturer's instructions. Dots indicate a single CRC sample. (C) For Western blot

analysis, ten independent human CRC specimens were used. For loading control, GAPDH

was used. (D) ImageJ (National Institute of Health, Bethesda, Maryland, USA) was used to

quantify protein expression, r.u, relative uncertainty, and P values were calculated by an

unpaired t-test. $p53^{WT}$, mainly detecting wild-type p53 (DO-1); $p53^{MT}$, mainly to detect mutant

p53 (Y5); $GSK3\beta^{pS9}$, the inactive form of $GSK3\beta$.

Figure 3. Multivariate analysis of the candidates and pathological factors related to survival in an independent set generated from the discovery cohort by applying random forest and then separated by before and after age 50. (a) p53^{WT}: wild-type p53 (DO-1), (b) p53^{MT}: mutant p53 (Y5), (c) GSK3β^{pS9}: the inactive form of GSK3β (the anti-GSK3β^{pS9} antibody), (d) Sex (Male): risk assessment for males compared to females, and (e) T3N0M0 including T1N0M0 and T2N0M0. *P* values are noted on the dashed line of HR weights. (A) Training and (B) testing sets.

Figure 4. Overall survival analysis using a Kaplan-Meier plot for an independent set. Each set was split into before and after age 50, and a Log-rank *p*-test was used. The median survival months and 95% CIs for the population under and over the age of 50 in the training and test sets were 124 (124-126), 99 (98-100), 124 (110-126), and 99 (97-126), respectively.

Table 1. Clinicopathological characteristics of the discovery cohort.

(a), SD, standard deviation.

Figure 5. Time-dependent ROC analysis for prognostic patient survival within a given time. The time was decided to maximize the ROC curve utilizing a weighted Cox regression. (A-B) Training and (C-D) testing sets, and the times for patients before (A, C) and after (B, D) age 50 were 123 and 137, respectively. p53^{WT}, mainly detecting wild-type p53 (DO-1), p53^{MT}; to detect mutant p53 (Y5), and GSK3β^{pS9}: the inactive form of GSK3β (the anti-GSK3β^{pS9} antibody).

Figure 6. Diagnostic analysis using the discriminant scores for each candidate as a single or whole. The receiver operating characteristic (ROC) curves of the discriminant scores for each candidate in the (A) training and (B) testing sets are shown. (C-F) Each set is divided into before (C, E) and after (D, F) age 50; a linear discriminant distribution for merged candidates

(left) and the ROC analysis using the discriminant score for the merged candidates (right) for diagnosing CRC are represented. The ratio of AUC and the corresponding 95% CI are noted. p53^{WT}; wild-type p53 (DO-1), p53^{MT}; mutant p53 (Y5), and GSK3β^{pS9}: the inactive form of GSK3β determined by the anti-GSK3β^{pS9} antibody. (A, C, D) Training and (B, E, F) testing sets.

REFERENCES

1 https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=total&sex=0&cancer=39&type=1&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=1&include_nmsc_other=1&half_pie=0&donut=0

2 https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html

3 Wang J, Li S, Liu Y, Zhang C, Li H, et al. Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis. *Cancer Med* 2020;9:361-373.

4 Colorectal Cancer Facts & Figures 2020-2022, American Cancer Society

5 Choi YJ, Lee DH, Han KD, Kim HS, Yoon H, et al. Optimal starting age for colorectal cancer screening in an era of increased metabolic unhealthiness: a nationwide Korean cross-sectional study. *Gut Liver* 2018;12:655-663.

6 https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening

7 Abualkhair WH, Zhou M, Ahnen D, Yu Q, Wu XC, et al. Trends in incidence of early-onset

colorectal cancer in the united states among those approaching screening age. *JAMA Netw*

Open 2020;3:e1920407.

8 Järvinen R, Knekt P, Hakulinen, T, Rissanen, H, Heliövaara M. Dietary fat, cholesterol and

colorectal cancer in a prospective study. *Br J Cancer* 2001;85:357-361.

9 Murphy N, Moreno V, Hughes DJ, Vodicka L, Vodicka P, et al. Lifestyle and dietary

environmental factors in colorectal cancer susceptibility. *Mol Aspects Med* 2019;69:2-

10 Carroll KL, Fruge AD, Heslin MJ, Lipke EA, Greene MW. Diet as a risk factor for early-

onset colorectal adenoma and carcinoma: a systematic review. *Front Nutr* 2022;9:896330.

11 Paraf F, Bouillot JC, Bruneval P. Cholesterol crystal embolisms in adenomatous polyposis

coli. *Ann Pathol* 1999;19:135-138.

12 Herbey II, Ivankova NV, Katkori VR, Mamaeva OA. Colorectal cancer and

hypercholesterolemia: review of current research. Exp Oncol 2005;27:166-178.

13 Brown DN, Caffa I, Cirmena G, Piras D, Garuti A, et al. Squalene epoxidase is a bona fide

oncogene by amplification with clinical relevance in breast cancer. *Sci Rep* 2016;6:19435.

14 Liu D, Wong CC, Fu Li, Chen H, Zhao L, et al. Squalene epoxidase drives NAFLD-induced

hepatocellular carcinoma and is a pharmaceutical target. *Sci Transl Med* 2018;10:eaap9840

15 Gill S, Stevenson J, Kristiana I, Andrew JB. Cholesterol-dependent degradation of

squalene monooxygenase, a control point in cholesterol synthesis beyond HMG-CoA

reductase. *Cell Metab* 2011;13:260-273.

16 Chua NK, Coates HW, Andrew JB. Squalene monooxygenase: a journey to the heart of

cholesterol synthesis. *Prog Lipid Res* 2020; 79:101033.

17 Jun SY, Andrew JB, Chua NK, Yoon JY, Lee JJ, et al. Reduction of squalene epoxidase

by cholesterol accumulation accelerates colorectal cancer progression and metastasis.

Gastroenterology 2021;160:1194-1207.

18 Idikio HA. Quantitative analysis of p53 expression in human normal and cancer tissue

microarray with global normalization method. *Int J Clin Exp Pathol* 2011;4:505-512.

19   https://training.seer.cancer.gov/colorectal/anatomy/

20 Stier EA, Chiao EY. Anal cancer and anal cancer precursors in women with a history of

HPV-related dysplasia and cancer. *Semin Colon Rectal Surg* 2017;28:97-101.

21 Kamarudin AN, Cox T, Kolamunnage-Dona R. Time-dependent ROC curve analysis in

medical research: current methods and applications. *BMC Med res Methodol* 2017;17:53.

22 Song SJ, Shim JE, Song WO. Trends in total fat and fatty acid intakes and chronic health

conditions in Korean adults over 2007-2015. *Public Health Nutr* 2019;22:1341-1350.

23 Clinton SK, Giovannucci EL, Hursting SD. The world cancer research fund/American

institute for cancer research third expert report on diet, nutrition, physical activity, and cancer:

impact and future directions. *J Nutr* 2020;150:663-671.

24 Fang Z, He M, Song M. Serum lipid profiles and risk of colorectal cancer: a prospective

cohort study in the UK biobank. *Br J Cancer* 2021;124:663-670.

25 Dessi S, Batetta B, Pulisci D, Spano O, Anchisi C, et al. Cholesterol content in tumor tissues

is inversely associated with high-density lipoprotein cholesterol in serum in patients with

gastrointestinal cancer. *Cancer* 1994;73:253:258.

26 Eggens I, Ekström TJ, Aberg F. Studies on the biosynthesis of polyisoprenols, cholesterol

and ubiquinone in highly differentiated human hepatomas. *J Exp Pathol* 1990;71:219-232.

27 Liu Y, Guo X, Wu L, Yang M, Li Z, et al. Lipid rafts promote liver cancer cell proliferation

and migration by upregulation of TLR_7 expression. *Oncotarget* 2016;7:63856-63869.

28   https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-

rates.html

29 https://www.strobe-statement.org/

30 Li C., Wang Y., Liu D., Wong C.C., Coker O.O., et al., Squalene epoxidase drives cancer

cell proliferation and promotes gut dysbiosis to accelerate colorectal carcinogenesis. *Gut*

2022;71:2253-2265.

*****Grant Support:** This work was supported by a Basic Science Research Program grant

through the National Research Foundation (NRF) of Korea funded by the Ministry of Science,

ICT and Future planning (2020R1A2C2006752) and the KRIBB Research Initiative Program

(KGM5222322) in the Republic of Korea.

*****Acknowledgements**

The authors wish to sincerely thank the following people: Dr. Andrew John Brown

(University of New South Wales) and Dr. Ngee Kiat Chua (The Walter and Eliza Hall Institute

of Medical Research) for advising our study and draft. Professor Austin and Courtney Givens,

RN, BSN (Korea Advanced Institute of Science and Technology) for assistance in the

preparation of this manuscript.

Figure 1. Involvement of SQLE, p53^WT, p53^MT, and GSK3β^pS9 in aging-dependent CRC progression.

Figure 2. Relevance of cholesterol augmentation in age-related CRC progression.

Figure 3. Multivariate analysis of the candidates and pathological factors related to survival in an independent set generated from the discovery cohort by applying random forest and then separated by before and after age 50

Figure 4. Overall survival analysis using a Kaplan-Meier plot for an independent set

Figure 5. Time-dependent ROC analysis for prognostic patient survival within a given time

Figure 6. Diagnostic analysis using the discriminant scores for each candidate as a single or whole

Table 1. Clinicopathological characteristics of the discovery cohort

Discovery phase	Case-control cohort		
All patients	1638		
Cohort size		Patients with Cancer	Control subjects
	n (%)	1311 (80.0%)	327 (20.0%)
Sex		Patients with Cancer	Control subjects
Male	n (%)	828 (63.1%)	201 (61.5%)
Female		483 (36.9%)	126 (38.5%)
Age	Overall	Patients with Cancer	Control subjects
Mean	57.1	57.4	56.3
Median ± SD[a]	58±13.9	58±13.5	66±15.3
Range (min - max)	24-86	24-86	25-82
Subtype		Patients with Cancer	Control subjects
Adenocarcinoma		1156 (88.2%)	-
Mucinous adenocarcinoma		145 (11.1%)	-
Papillary carcinoma	n (%)	9 (0.7%)	-
Signet-ring cell carcinoma		1 (0.0%)	-
Control		-	327
AJCC stage		Patients with Cancer	Control subjects
S1 - S2		471 (35.9%)	-
S3 - S4	n (%)	800 (61.0%)	-
unknown		40 (3.1%)	-
Control		-	327
The TNM staging		Patients with Cancer	Control subjects
T3N0M0 (T1N0M0, T2N0M0)		213 (16.2%)	-
T3N1M0 (T3N1M1)		295 (22.5%)	-
T3N2M0 (T3N2M1)		193 (14.7%)	-
T4N0M0 (T4N0M1)		218 (16.6%)	-
T4N1M0 (T4N1M1)		145 (11.1%)	-
T4N2M0 (T4N2M1)		158 (12.1%)	-
unknown		89 (6.8%)	-
Control		-	327
Tumour differentiation		Patients with Cancer	Control subjects
G1		396 (30.2%)	-
G2	n (%)	646 (49.3%)	-
G3		162 (12.4%)	-
Control		107 (8.1%)	-
Follow up	Overall	Patients with Cancer	Control subjects
Mean	93.6	91.7	101.9
Median ± SD	110±43.1	109±43.4	123±40.4
Range (min - max)	2-166	2-166	30-166